Document Type : original article


1 1. Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2. Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


Background: Juvenile Idiopathic Arthritis (JIA) is a chronic rheumatic disorder commonly affecting children younger than 16. The incidence and prevalence of JIA can vary greatly depending on ethnicity, genetic background, and socioeconomic status within different populations. Epidemiological studies play an essential role in planning successful treatment for chronic diseases like JIA and providing appropriate care measures in specific geographic regions.
Methods: In this cross-sectional study, 149 children were referred to the pediatric rheumatology department of Akbar Hospital in Mashhad from 2016 to 2019. Data was collected from all children within the first six months of disease onset, including the number of affected joints, demographic characteristics, systemic symptoms, extra-articular manifestations, and medication regimens.
Results: The most prevalent subtype of JIA is Oligoarticular, followed by Systemic JIA at 25.5%. Among children with enthesitis-related arthritis, more girls than boys were affected. Additionally, the most frequently affected joints in children were those of the lower limb. 5.4% of the total, had involvement of lumbosacral and sacroiliac joints. Serositis was observed in 2% of the patients. Uveitis was detected in 4 out of 154 patients (2.6%); 3 of these cases were chronic anterior uveitis, while one was acute anterior uveitis. 3 children (2%) were reported to have Macrophage Activation Syndrome (MAS).
Conclusion: Diagnosing juvenile idiopathic arthritis and other rheumatic diseases in children can often be delayed due to physicians’ lacking adequate clinical knowledge. To properly manage this chronic childhood illness, it is crucial to identify its symptoms and clinical course. This study represents the most comprehensive research conducted on children with JIA in the Northeast of Iran.


  1. Al-Mayouf SM, Al Mutairi M, Bouayed K, Habjoka S, Hadef D, Lotfy HM, Scott C, Sharif EM, Tahoun N. Epidemiology and demographics of juvenile idiopathic arthritis in Africa and the Middle East. Pediatric Rheumatology. 2021; 19(1):1-30.
  2. Costello R, McDonagh J, Hyrich KL, Humphreys JH. Incidence and prevalence of juvenile idiopathic arthritis in the United Kingdom, 2000–2018: results from the Clinical Practice Research Datalink. Rheumatology. 2022; 61(6):2548-54.
  3. Hata T, Hirata A, Ota R, Hosohata K, Nishihara M, Neo M, Katsumata T. Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database. Therapeutics and Clinical Risk Management. 2022:843-53.
  4. Horneff G, Borchert J, Heinrich R, Kock S, Klaus P, Dally H, Hagemann C, Diesing J, Schönfelder T. Incidence, prevalence, and comorbidities of juvenile idiopathic arthritis in Germany: a retrospective observational cohort health claims database study. Pediatric Rheumatology. 2022; 20(1):1-13.
  5. Bansal N, Pasricha C, Kumari P, Jangra S, Kaur R, Singh R. A comprehensive overview of juvenile idiopathic arthritis: From pathophysiology to management. Autoimmunity Reviews. 2023; 22(7):103337.
  6. Borocco C, Anselmi F, Rossi-Semerano L. Contribution of Ultrasound in Current Practice for Managing Juvenile Idiopathic Arthritis. Journal of Clinical Medicine. 2022; 12(1):91.
  7. Khawaja K, Kalas R, Almasri N. Subtype frequency, demographic features, treatment and outcome of Juvenile Arthritis in one Centre in Abu Dhabi in the United Arab Emirates. Pediatric Rheumatology. 2023; 21(1):14.
  8. Nossent JC, Kelty E, Keen H, Preen D, Inderjeeth C. Systemic juvenile idiopathic arthritis: frequency and long-term outcome in Western Australia. Rheumatology International. 2023; 43(7):1357-62.
  9. Phillips R. A safe and effective treatment for MAS. Nature Reviews Rheumatology. 2023:1-.
  10. Al‐Mayouf SM, Alrasheedi A, Almsellati I, Hashad S, Khawaja K, Abdwani R, AlHashim S, Muzaffer M, Lotfy H, Almutairi N. Familial aggregation of juvenile idiopathic arthritis with other autoimmune diseases: Impact on clinical characteristics, disease activity status, and disease damage. International Journal of Rheumatic Diseases. 2021; 24(8):1080-5.
  11. Berard R, Ng HY, Human A, Piskin D, Dhalla M, Gottlieb C, Batthish M, Chédeville G, Forest C, Fortin E, Gardiner J, Gerhold K, Jastrzebski A, Lang B, Miettunen PMH, Morgenstern S, Morin MP, Rosenberg A, Rumsey DG, Solarte CE, Tehrani N, Duffy KW, Pardo JP, Hazlewood GS, Levy DM. Canadian Rheumatology Association recommendations for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. The Journal of Rheumatology. 2023; 50(3):390-9.
  12. Cannon L. Biologics to the rescue: changing the treatment paradigm in juvenile idiopathic arthritis. Contemporary Pediatrics. 2023; 40(3):7-13.
  13. Acharya NR, Ebert CD, Kelly NK, Porco TC, Ramanan AV, Arnold BF. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomized controlled trial. Trials. 2020; 21:1-12.
  14. Melki I, Frémond M-L. JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases. Journal of Clinical Medicine. 2023; 12(14):4695.